This ICR collects information from sponsors and applicants who wish to obtain a priority review designation or breakthrough therapy designation. Respondents to the collection are manufacturers or sponsors of drug and/or biologic products.
The latest form for Expedited Programs for Serious Conditions-Drugs and Biologics expires 2021-04-30 and can be found here.
Document Name |
---|
Supporting Statement A |
Revision of a currently approved collection | 2024-08-23 | ||
Withdrawn and continue |
Extension without change of a currently approved collection | 2024-07-22 | |
Withdrawn and continue |
Revision of a currently approved collection | 2024-04-18 | |
Approved without change |
Extension without change of a currently approved collection | 2021-03-26 | |
Approved without change |
No material or nonsubstantive change to a currently approved collection | 2018-09-25 | |
Approved without change |
Revision of a currently approved collection | 2018-02-13 | |
Approved without change |
Extension without change of a currently approved collection | 2017-03-15 | |
Approved without change |
New collection (Request for a new OMB Control Number) | 2013-12-31 |
Federal Enterprise Architecture: Health - Consumer Health and Safety